Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …

Background: Patient-level surveillance of antimicrobial use (AMU) in Canadian hospitals
empowers the reduction of inappropriate AMU and was piloted in 2017 among 14 hospitals in …

Background Lower respiratory tract infections are common in adult patients with cystic fibrosis
(CF) and are frequently caused by Pseudomonas aeruginosa, resulting in chronic lung …

The purpose of this study was to evaluate the impact of augmented prophylaxis (ciprofloxacin
augmented with an aminoglycoside) compared with that of empirical prophylaxis (…

Background Acute pulmonary exacerbation (APE) in cystic fibrosis patients is frequent and
associated with a decline in pulmonary function, quality of life and survival. Tobramycin is …

2.1. Abstract Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic
commonly prescribed in intensive care unit setting. Admitted patients often show large …

Background Cystic fibrosis is a lethal inherited disease that affects multiple organs. To
provide optimal pharmacological treatment of comorbidities associated with cystic fibrosis, …

Background and Objectives Although dose optimization studies have been performed for
piperacillin and tazobactam separately, a combined integral analysis is not yet reported. As …

Background and Objective Clavulanic acid is a commonly used β-lactam inhibitor in pediatrics
for a variety of infections. Clear insight into its mode of action is lacking, however, and a …

Background The pharmacodynamic (PD) efficacy target of amoxicillin is 40% time above the
minimal inhibition concentration (40%T > MIC). Recent studies of other antibiotics have …